BRENDA M. SANDMAIER, M.D.
Brenda M. Sandmaier, M.D., Named ASTCT 2022-2023 President CHICAGO, April 26, 2022 (GLOBE NEWSWIRE) -- American Society for Transplantation and Cellular Therapy (ASTCT) announced Brenda M. Sandmaier, M.D., as the ASTCT President in 2022-2023.  Dr....
22157.jpg
Global Immune Checkpoint Inhibitors Market to 2027 - Size, Share & Industry Trends Analysis Report
26 avr. 2022 06h43 HE | Research and Markets
Dublin, April 26, 2022 (GLOBE NEWSWIRE) -- The "Global Immune Checkpoint Inhibitors Market Size, Share & Industry Trends Analysis Report By Application (Lung Cancer, Bladder Cancer, Melanoma,...
2020-11 Tessa Logo.jpg
Tessa Therapeutics Appoints Wilson W. Cheung as Chief Financial Officer
04 avr. 2022 06h00 HE | Tessa Therapeutics Ltd
SINGAPORE, April 04, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and...
2020-11 Tessa Logo.jpg
Tessa Therapeutics Showcases Positive Clinical Data from Phase 1 Study of “Off the Shelf” CD30 Cell Therapy at 2021 Annual Meeting of American Society of Hematology (ASH)
11 déc. 2021 18h00 HE | Tessa Therapeutics Ltd
Oral poster presentation highlights data from dose-escalation trial of allogeneic CD30.CAR EBVST cell therapy (TT11X) in patients with relapsed or refractory CD30-positive lymphomas Results...
22157.jpg
Global Diffuse Large B-cell Lymphoma (DLBCL) Competitive Landscape 2021
03 déc. 2021 04h23 HE | Research and Markets
Dublin, Dec. 03, 2021 (GLOBE NEWSWIRE) -- The "Diffuse Large B-cell Lymphoma (DLBCL) - Competitive Landscape in 2021" report has been added to ResearchAndMarkets.com's offering.The "Diffuse Large...
22157.jpg
Tyrokinse Kinase Inhibitors in the Global Oncology Market 2021: Market Leaders by Indication and Product
05 nov. 2021 05h58 HE | Research and Markets
Dublin, Nov. 05, 2021 (GLOBE NEWSWIRE) -- The "Oncology Markets for Tyrokinse Kinase Inhibitors" report has been added to ResearchAndMarkets.com's offering. Traditional cancer therapy has focused...
Zai Lab logo .png
Zai Lab Announces First Patient Treated in Greater China Portion of Potentially Registrational, Global Phase 2 Study of Odronextamab
25 oct. 2021 07h30 HE | Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
22157.jpg
Global Chronic Lymphocytic Leukemia (CLL) Disorder Clinical Market Report 2021-2027
06 juil. 2021 08h08 HE | Research and Markets
Dublin, July 06, 2021 (GLOBE NEWSWIRE) -- The "Chronic Lymphocytic Leukemia (CLL)" report has been added to ResearchAndMarkets.com's offering. Chronic lymphocytic leukemia (CLL) is a disorder where...
22157.jpg
Global Mantle Cell Lymphoma Clinical Landscape Market Report 2021: J&J has the Highest Number of Completed Clinical Trials with 15
21 juin 2021 04h38 HE | Research and Markets
Dublin, June 21, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Mantle Cell Lymphoma" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Mantle Cell...
22157.jpg
Global Cutaneous T-Cell Lymphoma (CTCL) Clinical Landscape Market 2021-2031: Treatments, Epidemiology, Marketed Drugs, Pipeline, Regulatory Events, Revenue Opportunity
16 juin 2021 05h03 HE | Research and Markets
Dublin, June 16, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Cutaneous T-Cell Lymphoma (CTCL)" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the...